… Migalastat, an oral pharmacological chaperone being developed as an alternative to
intravenous enzyme replacement therapy … of migalastat on renal function in patients with Fabry …

… replacement therapy (ERT) with agalsidase alfa or beta, and the oral pharmacological
chaperone migalastat. … on the effects of switching from ERT to migalastat, we performed a single-…

… who were previously on enzyme replacement therapy and switched to migalastat. In this …
of switching from enzyme replacement therapy to migalastat in patients with Fabry disease and “…

… Migalastat, the oral pharmacologic chaperone … than enzyme-replacement therapy given
every 2 weeks. The higher volume of distribution of migalastat than of enzyme replacement 11 …

… Oral migalastat is the first pharmacological chaperone approved for … Fabry disease who
have a migalastat-amenable GLA mutation. In the FACETS trial in enzyme replacement therapy (…

… Disease-specific management of FD includes enzyme replacement therapy with
agalsidase α and β or pharmacological oral chaperone migalastat. Migalastat is a low-molecular-mass …

… The usual treatment of FD is enzyme replacement therapy (ERT)… and since a few years ago
chaperone therapy Migalastat [17]. In … Oral chaperone therapy with Migalastat in patients with …

… patients who did not receive Fabry-specific therapy before migalastat (therapy-naive group;
… from enzyme replacement therapy to migalastat (previous enzyme replacement therapy …

… Thus, the first oral Fabry-specific drug in form of the chaperone Migalastat (Galafold … treatment
options In 2020 there are two different Fabry-specific therapy approaches with three drug …

… In summary, migalastat HCl is a candidate pharmacological chaperone that provides a … oral
small molecule pharmacological chaperone, rather than using enzyme replacement therapy, …